CytomX Therapeutics Inc (NASDAQ: CTMX) has a price-to-earnings ratio of 4.46x that is above its average ratio. Additionally, the 36-month beta value for CTMX is 2.08. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 3 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for CTMX is 103.99M and currently, short sellers hold a 18.23% ratio of that float. The average trading volume of CTMX on June 26, 2025 was 4.95M shares.
CTMX) stock’s latest price update
CytomX Therapeutics Inc (NASDAQ: CTMX)’s stock price has increased by 3.27 compared to its previous closing price of 2.14. However, the company has seen a -7.14% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-29 that SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 2:35 p.m. ET.
CTMX’s Market Performance
CytomX Therapeutics Inc (CTMX) has experienced a -7.14% fall in stock performance for the past week, with a -0.90% drop in the past month, and a 259.29% rise in the past quarter. The volatility ratio for the week is 7.00%, and the volatility levels for the past 30 days are at 7.10% for CTMX. The simple moving average for the past 20 days is -11.52% for CTMX’s stock, with a 92.95% simple moving average for the past 200 days.
Analysts’ Opinion of CTMX
Many brokerage firms have already submitted their reports for CTMX stocks, with H.C. Wainwright repeating the rating for CTMX by listing it as a “Buy.” The predicted price for CTMX in the upcoming period, according to H.C. Wainwright is $5 based on the research report published on May 15, 2025 of the current year 2025.
Piper Sandler, on the other hand, stated in their research note that they expect to see CTMX reach a price target of $2.50, previously predicting the price at $3.25. The rating they have provided for CTMX stocks is “Overweight” according to the report published on April 14th, 2025.
Piper Sandler gave a rating of “Overweight” to CTMX, setting the target price at $3.50 in the report published on May 28th of the previous year.
CTMX Trading at 24.87% from the 50-Day Moving Average
After a stumble in the market that brought CTMX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -28.59% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CTMX starting from Ogden Christopher, who sale 10,614 shares at the price of $2.69 back on Jun 16 ’25. After this action, Ogden Christopher now owns 226,271 shares of CytomX Therapeutics Inc, valued at $28,540 using the latest closing price.
Ogden Christopher, the Chief Financial Officer of CytomX Therapeutics Inc, sale 1,641 shares at $2.95 during a trade that took place back on Jun 13 ’25, which means that Ogden Christopher is holding 199,385 shares at $4,841 based on the most recent closing price.
Stock Fundamentals for CTMX
Current profitability levels for the company are sitting at:
- 0.24 for the present operating margin
- 0.65 for the gross margin
The net margin for CytomX Therapeutics Inc stands at 0.28. The total capital return value is set at 0.74.
Based on CytomX Therapeutics Inc (CTMX), the company’s capital structure generated 0.25 points at debt to capital in total, while cash flow to debt ratio is standing at -9.97.
Currently, EBITDA for the company is 26.76 million with net debt to EBITDA at -1.07. When we switch over and look at the enterprise to sales, we see a ratio of 2.09. The receivables turnover for the company is 75.44for trailing twelve months and the total asset turnover is 1.5. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.73.
Conclusion
In conclusion, CytomX Therapeutics Inc (CTMX) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
